Stay Informed on the CRI Website
January 21, 2014 |
It’s a new year here at the Cancer Research Institute and, with all the excitement buzzing around our organization and the naming of cancer immunotherapy as Science magazine’s 2013 breakthrough of the year, we’re never short of great news and stories on our website. We encourage you to stay informed by reading, sharing, and commenting on our blog, subscribing to our monthly e-newsletter, Cancer ImmuNews, or joining in on the conversation on Facebook, Twitter, or any of our other social media channels.
While our blog is the primary place where you can find the latest updates on the field of cancer immunotherapy from CRI, including scientific breakthroughs and program announcements, you can also check out other CRI publications, like our print newsletter, The Researcher. The Winter issue, which is now available for download, highlights serial tech entrepreneur Sean Parker’s generous $1 million gift to CRI to advance cancer immunotherapy research, photos from our 27th annual awards dinner, and the unique strategy and innovative model of CRI’s Clinical Accelerator program.
The latest Researcher issue also spotlights two new members of our community, including Kevin Lankes, a young New York City fiction writer who survived melanoma by being treated with the immunotherapy interferon, and community fundraiser Penny Bolton, who raised $31,000 from her ‘Bras for a Cause’ charity event for CRI. Stories are the most powerful way of raising awareness about cancer immunotherapy and enlisting more people to join in the movement to end cancer through immune-based treatments. You can read their stories and meet other patients like lung cancer survivor Ivan Kos, donors and supporters like YouTuber Mark Fischbach, and scientists like CRI investigator Dr. Carl June at www.cancerresearch.org/stories.
Stay informed with CRI and share your story
with us to help provide others hope, inspiration, and guidance to people all over the world who want to fight the disease with safer, more effective cancer immunotherapies.